Straumann Holding AG

“Straumann's implant core is genuinely exceptional — stacked switching costs, 60 years of clinical evidence, high tangible ROIC, and family-controlled long-term governance — but the ClearCorrect aligner venture carries no structural moat against Align Technology and has diluted incremental group ROIC to sub-WACC levels. At CHF 87.66 and 24x forward earnings, the market prices a 5% terminal growth rate with no discount for structural aligner drag, China VBP headwinds, or decelerating EM growth. Ten-year base-case returns are 1.5–2x total, insufficient for new capital. The business belongs on every quality investor's watchlist; the entry point does not yet justify ownership.”